NRGN and primary progressive aphasia: This observation aligns with previous cross-disease investigations conducted by Wellington et al.58 and Portelius et al.59, where NRGN levels were elevated in AD but not in FTD, Lewy body dementia, Parkinson’s disease, multiple system atrophy, PSP, PPA, ALS, or CBS.